Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Artrya Limited ( (AU:AYA) ) has shared an announcement.
Artrya Limited has reported significant progress in its U.S. market expansion, highlighted by the successful integration with Tanner Health and the FDA clearance of its Salix® Coronary Plaque module. These milestones, along with a substantial capital raise of A$80M, position Artrya to accelerate its commercial operations and expand its customer base in the U.S. market. The company is also preparing for the SAPPHIRE study, which aims to advance coronary artery disease diagnostics, particularly focusing on women, and is set to commence in early 2026.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is a medical technology company focused on the global commercialization of its AI-powered cloud platform, Salix®, which provides real-time, point-of-care assessment and management of coronary artery disease. The company is actively expanding its presence in the U.S. market, leveraging its innovative technology to enhance coronary health diagnostics.
Average Trading Volume: 813,692
Technical Sentiment Signal: Buy
Current Market Cap: A$577.6M
See more insights into AYA stock on TipRanks’ Stock Analysis page.